Technical Analysis for SCYX - SCYNEXIS, Inc.

Grade Last Price % Change Price Change
grade D 1.17 7.34% 0.08
SCYX closed up 7.34 percent on Wednesday, September 18, 2019, on 7.49 times normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline. Its advance stalled at its 200 day moving average, an important long-term support / resistance line.

Earnings due: Sep 27

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Flat Up Up
See historical SCYX trend table...

Date Alert Name Type % Chg
200 DMA Resistance Bearish 0.00%
Crossed Above 20 DMA Bullish 0.00%
Crossed Above 50 DMA Bullish 0.00%
MACD Bullish Centerline Cross Bullish 0.00%
New Uptrend Bullish 0.00%
Expansion Pivot Buy Setup Bullish Swing Setup 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Volume Surge Other 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
Wide Range Bar Range Expansion 0.00%

Older signals for SCYX ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
SCYNEXIS, Inc., a pharmaceutical company, is engaged in the discovery, development, and commercialization of anti-infectives to address unmet therapeutic needs. It is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug, which has completed Phase I clinical trials for the treatment of serious and life-threatening invasive fungal infections in humans against a range of Candida and Aspergillus fungal species, including drug resistant strains. The company, through its proprietary platform for cyclophilin inhibitors, is also developing clinical stage compounds, including SCY-635, an orally available cyclophilin inhibitor that has demonstrated clinical activity against Hepatitis C virus as a single agent and when dosed in combination with pegylated interferon and ribavirin; and SCY-641, a cyclophilin inhibitor with activity similar to cyclosporine, the active ingredient in Restasis and Optimmune drugs currently approved for dry eye disease in humans and dogs, respectively. In addition, it provides contract research and development services. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was founded in 1999 and is headquartered in Durham, North Carolina.
Medicine Medical Specialties Pharmaceutical Drugs Medication Anti Infectives Hepatitis C Interferon Pegylation
Is SCYX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 1.9
52 Week Low 0.35
Average Volume 233,154
200-Day Moving Average 1.175
50-Day Moving Average 1.13
20-Day Moving Average 1.104
10-Day Moving Average 1.108
Average True Range 0.0579
ADX 31.32
+DI 25.3606
-DI 15.0783
Chandelier Exit (Long, 3 ATRs ) 1.0663
Chandelier Exit (Short, 3 ATRs ) 1.1837
Upper Bollinger Band 1.1548
Lower Bollinger Band 1.0532
Percent B (%b) 1.15
BandWidth 9.202899
MACD Line 0.0009
MACD Signal Line -0.0071
MACD Histogram 0.008
Fundamentals Value
Market Cap 31.26 Million
Num Shares 26.7 Million
EPS -0.96
Price-to-Earnings (P/E) Ratio -1.22
Price-to-Sales 193.40
Price-to-Book 1.56
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.38
Resistance 3 (R3) 1.38 1.31 1.35
Resistance 2 (R2) 1.31 1.26 1.31 1.33
Resistance 1 (R1) 1.24 1.22 1.28 1.24 1.32
Pivot Point 1.17 1.17 1.19 1.17 1.17
Support 1 (S1) 1.10 1.12 1.14 1.10 1.02
Support 2 (S2) 1.03 1.08 1.03 1.01
Support 3 (S3) 0.96 1.03 1.00
Support 4 (S4) 0.96